Indo-Bangla Pharmaceuticals (DHA:IBP) Net Income (Continuing Operations): BDT0.00 Mil (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:IBP Indo-Bangla Pharmaceuticals Ltd DHA:IBP
32 GF Score
Price BDT17.30
View Full Analysis

What is Indo-Bangla Pharmaceuticals Net Income (Continuing Operations)?

Indo-Bangla Pharmaceuticals DHA:IBP +0.58% 32 Net Income (Continuing Operations) is BDT0.00 Mil as of . 20. GuruFocus rates DHA:IBP with a GF Score™ of 32/100.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Indo-Bangla Pharmaceuticals's Net Income (Continuing Operations) for the six months ended in . 20 was BDT0.00 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in . 20 was BDT0.00 Mil.

Indo-Bangla Pharmaceuticals  (DHA:IBP) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Indo-Bangla Pharmaceuticals Net Income (Continuing Operations) Related Terms

Indo-Bangla Pharmaceuticals Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Indo-Bangla Pharmaceuticals's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indo-Bangla Pharmaceuticals Net Income (Continuing Operations) Chart

Indo-Bangla Pharmaceuticals Annual Data
Trend
Net Income (Continuing Operations)

Indo-Bangla Pharmaceuticals Semi-Annual Data
Net Income (Continuing Operations)
DHA:IBP
32GF Score
Indo-Bangla Pharmaceuticals Ltd DHA:IBP
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indo-Bangla Pharmaceuticals Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in . 20 was BDT0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of BDT0.00 Mil mean?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a Net Income (Continuing Operations) of BDT0.00 Mil as of . 20. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Indo-Bangla Pharmaceuticals and its competitors.
Is Indo-Bangla Pharmaceuticals' Net Income (Continuing Operations) too high?
Indo-Bangla Pharmaceuticals' current Net Income (Continuing Operations) is BDT0.00 Mil. Overall, Indo-Bangla Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Indo-Bangla Pharmaceuticals' Net Income (Continuing Operations) compare to ?
Indo-Bangla Pharmaceuticals' Net Income (Continuing Operations) of BDT0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Drug Manufacturers company?
A good Net Income (Continuing Operations) depends on the Drug Manufacturers industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Indo-Bangla Pharmaceuticals and its competitors. Indo-Bangla Pharmaceuticals's current Net Income (Continuing Operations) is BDT0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo-Bangla Pharmaceuticals stock overvalued right now?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a current Net Income (Continuing Operations) of BDT0.00 Mil. The current Net Income (Continuing Operations) is BDT0.00 Mil. Indo-Bangla Pharmaceuticals' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Indo-Bangla Pharmaceuticals (DHA:IBP), the current Net Income (Continuing Operations) is BDT0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Indo-Bangla Pharmaceuticals Business Description

Comparable Companies
Address Ahmed Akbar Sobhan Road, Block B, Plot No. 183, 6th Floor, Bashundhara R/A, Baridhara, Dhaka, BGD, 1229
Indo-Bangla Pharmaceuticals Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products. The products of the company include human drugs dosages form such as tablets, capsules, syrup, oral saline, and suspension. The products of the company are sold in the domestic market.
32GF Score

Get the complete analysis for DHA:IBP

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT17.30
Price